+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Pipeline Review, H2 2018

  • ID: 4621790
  • Drug Pipelines
  • September 2018
  • Region: Global
  • 83 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Arvinas Inc
  • Atossa Genetics Inc
  • Eagle Pharmaceuticals Inc
  • EndoCeutics Inc
  • Huons Global Co Ltd
  • Nuevolution AB
  • MORE
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Pipeline Review, H2 2018

Summary

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) pipeline Target constitutes close to 28 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Estrogen Receptor - Pipeline Review, H2 2018, outlays comprehensive information on the Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Estrogen receptor alpha (ERA) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR1. It is involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. It decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displaces RELA/p65 and associated co-regulators from the promoter.

It recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 2, 3, 10 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health, Metabolic Disorders, Central Nervous System and Male Health which include indications Breast Cancer, Metastatic Breast Cancer, Endometriosis, Hormone Sensitive Breast Cancer, Osteoporosis, Alzheimer's Disease, Bipolar Disorder (Manic Depression), Carcinomas, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Demyelinating Diseases, Ductal Carcinoma In Situ, Endometrial Cancer, Fallopian Tube Cancer, Lung Cancer, Male Hypogonadism, Multiple Sclerosis, Neuromyelitis Optica (Devic’s Syndrome), Ovarian Cancer, Peritoneal Cancer, Prostate Cancer and Vasomotor Symptoms of Menopause (Hot Flashes).

Furthermore, this report also reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)
  • The report reviews Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Arvinas Inc
  • Atossa Genetics Inc
  • Eagle Pharmaceuticals Inc
  • EndoCeutics Inc
  • Huons Global Co Ltd
  • Nuevolution AB
  • MORE
Introduction

Report Coverage

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Overview

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Companies Involved in Therapeutics Development

Arvinas Inc

AstraZeneca Plc

Atossa Genetics Inc

Avivia BV

Eagle Pharmaceuticals Inc

Endece LLC

EndoCeutics Inc

H3 Biomedicine Inc

Huons Global Co Ltd

Novartis AG

Nuevolution AB

Shenogen Pharma Group Ltd

ViroMed Co Ltd

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Drug Profiles

(bazedoxifene acetate + cholecalciferol) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acolbifene + GnRH Agonist + prasterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acolbifene + prasterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acolbifene hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARV-378 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARV-471 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dehydrodiconiferyl alcohol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-372 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Endoxifen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ERX-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosfestrol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H-3B5942 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H-3B6545 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Libidua - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Loseasonique - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDC-1308 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ESR1 and VEGFR2 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize ER Alpha for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize ER-Alpha for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize ER-Alpha for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Estrogen Receptor Alpha for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNG-1153 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNG-8023 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-16234 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTC-352 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZB-716 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Dormant Products

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Discontinued Products

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Product Development Milestones

Featured News & Press Releases

Jul 10, 2018: Cancer Discovery Features H3 Biomedicine Paper Highlighting Effects of Selective Estrogen Receptor Covalent Antagonists (SERCAs) in ERa Wild-Type and Mutant Breast Cancer Models

Jun 01, 2018: ENDECE Attending 2018 Bio International in Boston

Mar 26, 2018: Mayne Pharma Launches Generic Quartette in the U.S., Another Womens Health Product

Mar 21, 2018: UIC breast cancer drug in first human clinical trial

Dec 20, 2017: Arvinas Nominates Oral Clinical Candidate for Estrogen Receptor Degrader Program

Dec 11, 2017: AstraZeneca’s Faslodex Rejects For Use Within NHS Scotland

Dec 08, 2017: Arvinas Presents New Data on Oral Estrogen Receptor PROTAC Degrader at 2017 San Antonio Breast Cancer Symposium

Dec 07, 2017: Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant

Dec 06, 2017: H3 Biomedicine Presents Preclinical Data on Novel ERa Antagonist at San Antonio Breast Cancer Symposium

Nov 15, 2017: Faslodex receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib

Nov 14, 2017: Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib

Oct 13, 2017: Faslodex (Fulvestrant) Receives Positive CHMP Opinion For The Treatment Of Hormone Receptor-Positive Advanced Breast Cancer In Combination With Palbociclib

Sep 05, 2017: H3 Biomedicine Announces First Patient Dosed with H3B-6545 in Phase 1 Study in Breast Cancer

Sep 01, 2017: NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective

Aug 30, 2017: UT Health San Antonio researchers developing drug for recurring ER-positive breast cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Arvinas Inc, H2 2018

Pipeline by AstraZeneca Plc, H2 2018

Pipeline by Atossa Genetics Inc, H2 2018

Pipeline by Avivia BV, H2 2018

Pipeline by Eagle Pharmaceuticals Inc, H2 2018

Pipeline by Endece LLC, H2 2018

Pipeline by EndoCeutics Inc, H2 2018

Pipeline by H3 Biomedicine Inc, H2 2018

Pipeline by Huons Global Co Ltd, H2 2018

Pipeline by Novartis AG, H2 2018

Pipeline by Nuevolution AB, H2 2018

Pipeline by Shenogen Pharma Group Ltd, H2 2018

Pipeline by ViroMed Co Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Arvinas Inc
  • AstraZeneca Plc
  • Atossa Genetics Inc
  • Avivia BV
  • Eagle Pharmaceuticals Inc
  • Endece LLC
  • EndoCeutics Inc
  • H3 Biomedicine Inc
  • Huons Global Co Ltd
  • Novartis AG
  • Nuevolution AB
  • Shenogen Pharma Group Ltd
  • ViroMed Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll